Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652058 | 0.99 | LMNA (0.49) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2652881 | 0.87 | LMNA (0.52) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2652777 | 0.86 | SLC6A3 (0.41) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2651763 | 0.86 | SLC6A3 (0.50) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2652580 | 0.84 | SLC6A3 (0.64) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2653533 | 0.82 | SLC6A3 (0.64) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2651736 | 0.82 | LMNA (0.42) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2651388 | 0.79 | LMNA (0.53) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2651596 | 0.77 | LMNA (0.51) | LMNASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL2652760 | 0.75 | GCK (0.55) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305301-B1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6608218-B2 | Such as 1-(cyclopentyloxy-(3,4-dichloro-phenyl)-acetyl)-3-methyl-urea for treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1305301-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-02 | — | — | EP | disclosed |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-12-26 | — | — | US | disclosed |
| US-6486184-B2 | 1-(CYCLOPENTYLOXY-(3,4-DICHLORO- PHENYL)-ACETYL)-3-METHYL-UREA FOR EXAMPLE; USE IN TREATING HYPERGLYCEMIA CHARACTERISTIC OF ALL TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2002008209-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | LMNA 4429/4885SLC6A3 2221/4885SLC6A2 2641/4885 |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | LMNA 4399/4885SLC6A3 2178/4885SLC6A2 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.